Convergence is coming: the delineations that currently separate medical devices and pharmaceuticals will increasingly dissolve. More and more product ideas and concepts incorporate elements of devices, drugs, and digital health. This convergence will require companies to rethink the entire commercialization model, lest they be left behind.
In her role as a consultant, Adrienne is a leader in DRG’s Commercial Consulting Group, consisting of a team of consultants located throughout North America and Europe. Her specific area of focus is to support leading medical device and technology companies on issues related to commercialization strategy, product and portfolio development, and market access. During her 10 year tenure at DRG, Adrienne has been instrumental in broadening the company’s expertise in market sizing and opportunity assessments, quantitative market modeling and scenario planning, due diligence, conjoint, customer loyalty and behavior, medical billing and claims-based research, and emerging technology adoption.
Adrienne regularly engages with industry partners to support professionals devoted to developing and using engineering and technology to advance human health and she sits on the Industry Advisory Board for the Biomedical Engineering Society (BMES). Adrienne is active as a guest lecturer for graduate programs at leading universities in North America where she leads discussions related to the impact of health care reform; the convergence of biopharma, medtech, and digital; and the opportunities for regenerative medicine diagnostics and therapeutics.